Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568423 · ClinicalTrials.gov registry record · Phase 1
A Study of Mirikizumab (LY3074828) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
NCT02568423 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 51 participants.
The verdict
NCT02568423, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
Study Summary
The main purpose of this study is to explore the safety and tolerability of mirikizumab in healthy Japanese and Caucasian participants. The study will also estimate how much mirikizumab gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 16 weeks for each participant.
Interventions
- DRUG Placebo - IV
- DRUG Placebo - SC
- DRUG Mirikizumab - IV
- DRUG Mirikizumab - SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2015-12-02 |
| Est. Completion | 2018-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568423
The ClinicalTrials.gov registry entry for NCT02568423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo - IV is the first listed.
NCT02568423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02568423 about?
NCT02568423 is a clinical study titled "A Study of Mirikizumab (LY3074828) in Healthy Participants". The main purpose of this study is to explore the safety and tolerability of mirikizumab in healthy Japanese and Caucasian participants. The study will also estimate how much mirikizumab gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 16 wee...
What is the current status of trial NCT02568423?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2015-12-02. Estimated completion is 2018-10-24.
What interventions are being tested in trial NCT02568423?
The interventions under investigation include: Placebo - IV (DRUG), Placebo - SC (DRUG), Mirikizumab - IV (DRUG), Mirikizumab - SC (DRUG).
Who is sponsoring clinical trial NCT02568423?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.